Dr. Gary L. Buchschacher
Claim this profileKaiser Permanente-Anaheim
Studies Colon Cancer
Studies Cervical Adenocarcinoma
14 reported clinical trials
34 drugs studied
Area of expertise
1Colon Cancer
Stage IV
Stage III
BRAF negative
2Cervical Adenocarcinoma
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Gary L. Buchschacher is currently running
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Perioperative Chemotherapy
for Pancreatic Cancer
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Recruiting4 awards Phase 318 criteria
More about Gary L. Buchschacher
Clinical Trial Related7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Gary L. Buchschacher has experience with
- Fluorouracil
- Irinotecan Hydrochloride
- Leucovorin
- Leucovorin Calcium
- Oxaliplatin
- Paclitaxel
Breakdown of trials Gary L. Buchschacher has run
Colon Cancer
Cervical Adenocarcinoma
Colorectal Cancer
Parotid Gland Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Gary L. Buchschacher specialize in?
Is Gary L. Buchschacher currently recruiting for clinical trials?
Are there any treatments that Gary L. Buchschacher has studied deeply?
What is the best way to schedule an appointment with Gary L. Buchschacher?
What is the office address of Gary L. Buchschacher?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.